Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement

Aethlon Medical, Inc. (Nasdaq: AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients.

Aethlon Medical is developing the Hemopurifier®, a first-in-class blood purification cartridge used to remove a range of different particles from the blood, including cancer promoting exosomes for the treatment of cancers with no adequate alternative therapy and viruses for the treatment of life-threatening viral diseases. SeaStar’s platform of cartridges include the CLR 2.0 Hemofilter which is FDA 510K cleared for acute kidney injury (AKI), congestive heart failure (CHF) and pulmonary edema and is currently being marketed for organ preservation in the solid organ transplant market.  Each company’s cartridges are designed to fit onto standard, hospital ICU-based equipment, either independently or together, and the companies plan to jointly develop complete treatment solutions that will allow deployment into multiple inpatient and outpatient treatment settings in any clinical indication where combined use of the Hemopurifier and CPCs may improve or expand indications for use, including but not limited to infectious disease, oncology and organ preservation and transplant.

“The potential synergy of our two companies’ platforms should allow penetration into multiple unaddressed markets,” said Timothy C. Rodell, M.D., Interim Chief Executive Officer of Aethlon Medical. “Many solid organ transplant patients’ outcomes are impacted by viral infections, including hepatitis C and cytomegalovirus (CMV), so the demonstrated ability of the Aethlon Hemopurifier to clear viruses could be complementary to SeaStar’s CLR 2.0’s ability to improve donor organ function.  Likewise, inflammation has a role in cancer, which could make the SeaStar products complementary to the Hemopurifier.”

“Aethlon and SeaStar align on combining their complementary novel medical devices to address critical unmet needs,” said Charles J. Fisher Jr., M.D., Chief Executive Officer of SeaStar Medical. “Combinations of the Hemopurifier and the SeaStar cartridges present unique and promising development paths. After joining Aethlon’s board of directors in November 2017, I realized that both teams are equally passionate about providing innovative medical products designed to improve the survival of patients with cancer, infectious and inflammatory disorders.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here